THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

There have been renewed calls for the introduction of a national screening programme for prostate cancer in the UK. Former ...

MDxHealth has 4 validated testing products with one more in the clinical pipeline. All are focused specifically on urology. The company expects to do ~$65-$70M of sales in 2023, but the valuation is a ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

To date, men undergoing screening through the measurement of prostate-specific antigen (PSA) levels have had a significant reduction in neoplastic mortality. Because of its low specificity, however, ...

A prostate cancer biomarker test that utilizes 17 genetic markers has demonstrated a high degree of accuracy in screening for serious cancer. The test also significantly reduced unnecessary biopsies ...

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.